You are currently viewing the abstract.View Full Text
Enrollment of patients in a clinical trial is difficult as a result of a host of well-documented barriers. In the field of oncology, molecularly targeted treatments have demonstrated considerable therapeutic promise. At the same time, clinical testing of these targeted agents has introduced new complexities in the decision-making process by patients or providers on whether to participate in clinical trials. Explored in this Commentary are challenges of and potential solutions for the clinical testing of modern cancer therapies.
Citation: R. L. Schilsky, Accrual to Cancer Clinical Trials in the Era of Molecular Medicine. Sci. Transl. Med. 3, 75cm9 (2011).
- Copyright © 2011, American Association for the Advancement of Science